Brain Changes in Responders vs. Non-Responders in Chronic Migraine: Markers of Disease Reversal
- PMID: 27766076
- PMCID: PMC5052273
- DOI: 10.3389/fnhum.2016.00497
Brain Changes in Responders vs. Non-Responders in Chronic Migraine: Markers of Disease Reversal
Abstract
The aim of this study was to identify structural and functional brain changes that accompanied the transition from chronic (CM; ≥15 headache days/month) to episodic (EM; <15 headache days/month) migraine following prophylactic treatment with onabotulinumtoxinA (BoNT-A). Specifically, we examined whether CM patients responsive to prophylaxis (responders; n = 11), as evidenced by a reversal in disease status (defined by at least a 50% reduction in migraine frequency and <15 headache days/month), compared to CM patients whose migraine frequency remained unchanged (non-responders; n = 12), showed differences in cortical thickness using surface-based morphometry. We also investigated whether areas showing group differences in cortical thickness displayed altered resting-state functional connectivity (RS-FC) using seed-to-voxel analyses. Migraine characteristics measured across groups included disease duration, pain intensity and headache frequency. Patient reports of headache frequency over the 4 weeks prior to (pre-treatment) and following (post-treatment) prophylaxis were compared (post minus pre) and this measure served as the clinical endpoint that determined group assignment. All patients were scanned within 2 weeks of the post-treatment visit. Results revealed that responders showed significant cortical thickening in the right primary somatosensory cortex (SI) and anterior insula (aINS), and left superior temporal gyrus (STG) and pars opercularis (ParsOp) compared to non-responders. In addition, disease duration was negatively correlated with cortical thickness in fronto-parietal and temporo-occipital regions in responders but not non-responders, with the exception of the primary motor cortex (MI) that showed the opposite pattern; disease duration was positively associated with MI cortical thickness in responders versus non-responders. Our seed-based RS-FC analyses revealed anti-correlations between the SI seed and lateral occipital (LOC) and dorsomedial prefrontal cortices (DMPFC) in responders, whereas non-responders showed increased connectivity between the ParsOp seed and LOC. Overall, our findings revealed distinct morphometric and functional brain changes in CM patients that reverted to EM following prophylactic treatment compared to CM patients that showed no change in disease status. Elucidating the CNS changes involved in disease reversal may be critical to discovering interventions that prevent or slow the progression of CM. Such changes may aid in the evaluation of treatments as well as provide markers for disease "de-chronification".
Keywords: BOTOX®; fMRI; gray matter; headache; migraine transformation; network connectivity; pain; preventative therapy.
Figures




Similar articles
-
Peripherally acting anti-CGRP monoclonal antibodies alter cortical gray matter thickness in migraine patients: A prospective cohort study.Neuroimage Clin. 2023;40:103531. doi: 10.1016/j.nicl.2023.103531. Epub 2023 Oct 14. Neuroimage Clin. 2023. PMID: 37866119 Free PMC article.
-
Functional connectivity of the visual cortex in chronic migraine before and after medication withdrawal therapy.Neuroimage Clin. 2023;40:103543. doi: 10.1016/j.nicl.2023.103543. Epub 2023 Nov 17. Neuroimage Clin. 2023. PMID: 37988998 Free PMC article.
-
Altered functional connectivity of the right caudate nucleus in chronic migraine: a resting-state fMRI study.J Headache Pain. 2022 Dec 2;23(1):154. doi: 10.1186/s10194-022-01506-9. J Headache Pain. 2022. PMID: 36460958 Free PMC article.
-
Cortical thickness studies in migraine: Current evidence and future directions.Cephalalgia. 2025 Jun;45(6):3331024251341204. doi: 10.1177/03331024251341204. Epub 2025 Jun 6. Cephalalgia. 2025. PMID: 40474701 Review.
-
Resting State Electrophysiological Cortical Activity: A Brain Signature Candidate for Patients with Migraine.Curr Pain Headache Rep. 2022 Apr;26(4):289-297. doi: 10.1007/s11916-022-01030-0. Epub 2022 Feb 19. Curr Pain Headache Rep. 2022. PMID: 35182303 Review.
Cited by
-
Shifting brain circuits in pain chronicity.Hum Brain Mapp. 2019 Oct 15;40(15):4381-4396. doi: 10.1002/hbm.24709. Epub 2019 Jul 12. Hum Brain Mapp. 2019. PMID: 31298464 Free PMC article.
-
Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact.Medicine (Baltimore). 2023 Jul 1;102(S1):e32600. doi: 10.1097/MD.0000000000032600. Medicine (Baltimore). 2023. PMID: 37499085 Free PMC article. Clinical Trial.
-
Botulinum toxin effects on biochemical biomarkers related to inflammation-associated head and neck chronic conditions: a systematic review of clinical research.J Neural Transm (Vienna). 2025 Mar 4. doi: 10.1007/s00702-024-02869-w. Online ahead of print. J Neural Transm (Vienna). 2025. PMID: 40035830 Review.
-
CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA.J Headache Pain. 2019 Apr 23;20(1):39. doi: 10.1186/s10194-019-0989-9. J Headache Pain. 2019. PMID: 31014225 Free PMC article.
-
OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine.Drugs. 2018 Apr;78(5):589-600. doi: 10.1007/s40265-018-0894-6. Drugs. 2018. PMID: 29532439 Free PMC article. Review.
References
-
- Allergan (2013). BOTOX (onabotulinumtoxinA) Full Prescribing Information. Irvine, CA: Allergan Inc.
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous